Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Astex Therapeutics Limited

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxogrouplimited

Anthony William James Cooper

David House

James Francis Callahan

Diane Mary Coe

Julie Nicole Hamblin

Keith Biggadike

Jeffrey Charles Boehm

Zehong Wan

Paul Bamborough

Xichen Lin

Jeffrey K Kerns

Nicole Cathleen Goodwin

Beth Adams Norton

James Michael Woolven

Graham George Adam Inglis

Paul Martin Gore

Iain McFarlane McLay

Neysa Nevins

Stefano Livia

Andrew Sharpe

Paul Spencer Jones

Emmanuel Hubert Demont

Vipulkumar Kantibhai Patel

Stephen John Atkinson

Charlotte Mary Griffiths-Jones

Kevin James Doyle

Jonathan Thomas Seal

Lee Andrew Harrison

Thomas Daniel Heightman

Charlotte Jane Mitchell

Mika Lindvall

Robert J Watson

Alexander G Preston

Hongxing Yan

Niall Andrew Anderson

Matthew John Lindon

Ian David Wall

Simon John Fawcett MacDonald

Alison Judith Redgrave

David George Allen

Martin Redpath Johnson

Gordon G Weingarten

Kenneth David Down

Caroline Mary Cook

Sebastien Andre Campos

Hendrika Maria Gerarda Willems

Thomas George Christopher Hayhow

Gemma Victoria White

Christopher David Edlin

Simon Peace

Philip Alan Skone

Nicholas Paul Barton

Helen Elizabeth Aylott

Edward Paul Cannons

Armelle Le Gall

Michael D Dowle

Ian B Campbell

Hong Nie

Stefan Senger

Sadie Vile

Steven Leslie Sollis

John Edward Robinson

Simon John Fawcett Macdonald

Heather Anne Barnett

Grahame Robert Woollam

Steven Philip Keeling

Haydn Terence Jones

Caroline Wilson

Vincent J Colandrea

Chelsea Ariane Huff

Joel Karpiak

Ian Baxter Campbell

Gordon Gad Weingarten

Matthew J Lindon

Beth A Norton

The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

Ether linked triazoles as NRF2 activators

The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I), 

Bisaryl amides as NRF2 activators

The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof: 

The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy 

Pyridinone dicarboxamide for use as bromodomain inhibitors

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.

Chemical compounds

The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.

Pyrazole compounds acting against allergic, immune and inflammatory conditions

The present invention relates to pyrazole amide derivatives pharmaceutical compositions containing these compounds and to their use in therapy.

Pyrazole compounds acting against allergic, inflammatory and immune disorders

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

N-pyrazolyl carboxamides as CRAC channel inhibitors

Novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.

7,8-dihydropyrido[2,3-d]pyrimidin-4-yl substituted compounds as inhibitors of p38 kinase

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or autoimmune conditions.

Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions

The present invention is directed to novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds, compositions, and use in therapy as CSBP/RK/p38 kinase inhibitors of Formulas (V) and (Va) wherein inter alia,

Compounds

The present invention provides compounds of formula (I): pharmaceutical compositions comprising the compounds and the use of the compounds for the manufacture of a medicament, particularly for the treatment of inflammation and/or allergic conditions.

The present invention provides compounds of formula (I): a process for their preparation, pharmaceutical compositions comprising the compounds and the preparation of said compositions, intermediates and use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or skin disease.

Growing community of inventors

Stevenage, United Kingdom

Anthony William James Cooper